Severin Investments LLC Has $497,000 Position in CVS Health Corporation $CVS

Severin Investments LLC cut its position in shares of CVS Health Corporation (NYSE:CVS) by 52.7% in the first quarter, Holdings Channel reports. The institutional investor owned 6,916 shares of the pharmacy operator’s stock after selling 7,705 shares during the period. Severin Investments LLC’s holdings in CVS Health were worth $497,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CVS. Kingsview Wealth Management LLC lifted its position in CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after buying an additional 79,340 shares in the last quarter. Hamlin Capital Management LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at about $160,844,000. Cresset Asset Management LLC raised its holdings in CVS Health by 56.8% during the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock worth $2,675,000 after acquiring an additional 12,849 shares in the last quarter. Capitolis Liquid Global Markets LLC bought a new stake in CVS Health during the third quarter worth about $11,308,000. Finally, National Bank of Canada FI boosted its position in CVS Health by 50.3% during the third quarter. National Bank of Canada FI now owns 1,770,840 shares of the pharmacy operator’s stock valued at $133,495,000 after purchasing an additional 593,015 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. Morgan Stanley increased their price objective on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Barclays raised their target price on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Argus upped their price target on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health has been featured in articles highlighting its strong fundamentals and recent move to a fresh 52-week high, suggesting investors still see room for upside if earnings and guidance remain solid.
• Positive Sentiment: The company’s marketing and brand-building efforts tied to America250 are reinforcing CVS Health’s public-facing profile, which may help support broader consumer engagement and brand strength.
• Neutral Sentiment: CVS Health also published health-screening content aimed at encouraging preventive care, which is positive for brand awareness but unlikely to move the stock on its own.
• Neutral Sentiment: A Wall Street Zen downgrade to Hold adds a cautious note, but it does not appear to be a major driver compared with the stock’s recent strength.
• Negative Sentiment: Florida has opened a probe into CVS Health over alleged pharmacy steering, raising the risk of regulatory scrutiny, possible legal costs, and renewed investor concern about pharmacy benefit manager practices. Florida probes CVS Health over alleged pharmacy steering
• Negative Sentiment: Industry coverage noting that UnitedHealth, Humana, and CVS have denied some post-hospital care at high rates could keep attention on utilization management and reimbursement practices, which may pressure sentiment around managed-care and pharmacy operations.

CVS Health Stock Performance

CVS opened at $103.59 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $106.15. The business has a 50 day moving average of $92.88 and a 200-day moving average of $82.79. The stock has a market cap of $132.17 billion, a price-to-earnings ratio of 45.63, a PEG ratio of 1.01 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the firm earned $2.25 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.